Hudson Bay Capital Management LP Lowers Stock Holdings in Drugs Made In America Acquisition Corp. $DMAA

Key Points

• Hudson Bay Capital Management LP cut its stake in Drugs Made In America Acquisition (NASDAQ:DMAA) by 13.9%, selling 250,000 shares to hold 1,550,000 shares (about 5.31%) worth $15.918 million at the end of the quarter.
• Several other institutions added or increased positions — including new stakes from Sandia, Quarry and JPMorgan Chase (≈$1.02M) and increases from Shaolin Capital and Bulldog Investors — indicating ongoing hedge-fund interest.
• DMAA shares traded near $10.51 (the 12‑month high) with 50-/200-day moving averages around $10.44/$10.36, and analysts maintain a consensus Sell rating (Weiss Ratings: "sell (d-)").

Hudson Bay Capital Management LP lowered its position in shares of Drugs Made In America Acquisition Corp. (NASDAQ:DMAA - Free Report) by 13.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,550,000 shares of the company's stock after selling 250,000 shares during the period. Hudson Bay Capital Management LP owned about 5.31% of Drugs Made In America Acquisition worth $15,918,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of DMAA. Sandia Investment Management LP bought a new position in shares of Drugs Made In America Acquisition during the 3rd quarter valued at about $161,000. Quarry LP bought a new stake in Drugs Made In America Acquisition in the 3rd quarter worth approximately $161,000. Shaolin Capital Management LLC boosted its stake in Drugs Made In America Acquisition by 50.0% in the third quarter. Shaolin Capital Management LLC now owns 150,000 shares of the company's stock worth $1,540,000 after buying an additional 50,000 shares in the last quarter. Bulldog Investors LLP grew its position in Drugs Made In America Acquisition by 78.5% during the third quarter. Bulldog Investors LLP now owns 130,264 shares of the company's stock valued at $1,338,000 after acquiring an additional 57,300 shares during the last quarter. Finally, JPMorgan Chase & Co. bought a new position in Drugs Made In America Acquisition during the third quarter valued at approximately $1,024,000.

Drugs Made In America Acquisition Stock Up 0.4%

Shares of NASDAQ:DMAA opened at $10.51 on Friday. The stock's 50-day moving average price is $10.44 and its 200-day moving average price is $10.36. Drugs Made In America Acquisition Corp. has a 12-month low of $10.00 and a 12-month high of $10.51.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a "sell (d-)" rating on shares of Drugs Made In America Acquisition in a report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has a consensus rating of "Sell".

Drugs Made In America Acquisition Profile

Drugs Made In America Acquisition Corp NASDAQ: DMAA is a special purpose acquisition company incorporated in Delaware with the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company's stated focus is on identifying and acquiring one or more operating businesses in the U.S. pharmaceutical sector, particularly those involved in the domestic manufacturing of approved drugs, active pharmaceutical ingredients or related contract development and manufacturing services.

Operating as a blank‐check vehicle, Drugs Made In America Acquisition holds its funds in a trust account pending the completion of an initial business combination.

Want to see what other hedge funds are holding DMAA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Drugs Made In America Acquisition Corp. (NASDAQ:DMAA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.